With a market capitalization (market cap) of $6.13B — a measure of how much the company is worth — Definium Therapeutics, Inc. is the 1271st most valuable company in Healthcare as of August 19, 2026. Shares trade at $46.18, up +2.03% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Visit websiteAs of August 19, 2026, Definium Therapeutics, Inc. (DFTX) is worth $6.13B — this is its market capitalization, the total value of all its outstanding shares.
Definium Therapeutics, Inc.’s market cap is $6.13B, which ranks it #1271 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Definium Therapeutics, Inc. (DFTX) shares trade at $46.18, up 2.03% on the day, as of August 19, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025